title: Selective interaction of heparin with the variable region 3 within surface glycoprotein of laboratory-adapted feline immunodeficiency virus.
abstract: Heparan sulfate proteoglycans (HSPG) can act as binding receptors for certain laboratory-adapted (TCA) strains of feline immunodeficiency virus (FIV) and human immunodeficiency virus (HIV). Heparin, a soluble heparin sulfate (HS), can inhibit TCA HIV and FIV entry mediated by HSPG interaction in vitro. In the present study, we further determined the selective interaction of heparin with the V3 loop of TCA of FIV. Our current results indicate that heparin selectively inhibits infection by TCA strains, but not for field isolates (FS). Heparin also specifically interferes with TCA surface glycoprotein (SU) binding to CXCR4, by interactions with HSPG binding sites on the V3 loop of the FIV envelope protein. Peptides representing either the N- or C-terminal side of the V3 loop and containing HSPG binding sites were able to compete away the heparin block of TCA SU binding to CXCR4. Heparin does not interfere with the interaction of SU with anti-V3 antibodies that target the CXCR4 binding region or with the interaction between FS FIV and anti-V3 antibodies since FS SU has no HSPG binding sites within the HSPG binding region. Our data show that heparin blocks TCA FIV infection or entry not only through its competition of HSPG on the cell surface interaction with SU, but also by its interference with CXCR4 binding to SU. These studies aid in the design and development of heparin derivatives or analogues that can inhibit steps in virus infection and are informative regarding the HSPG/SU interaction.
authors.affiliation: School of Medicine, Taizhou University, Taizhou, Zhejiang, China; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States.
authors.forename: Qiong-Ying
authors.initials: QY
authors.lastname: Hu
authors.affiliation: Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fink
authors.affiliation: Custom Monoclonals International, Inc., W. Sacramento, California, United States.
authors.forename: Chris K
authors.initials: CK
authors.lastname: Grant
authors.affiliation: Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States.
authors.forename: John H
authors.initials: JH
authors.lastname: Elder
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D002415:Cats; D002460:Cell Line; D019812:Heparan Sulfate Proteoglycans / Q000737:chemistry / Q000378:metabolism*; D006493:Heparin / Q000494:pharmacology*; D016089:Immunodeficiency Virus, Feline / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D011485:Protein Binding; D019718:Receptors, CXCR4 / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism
chemical_list: D019812:Heparan Sulfate Proteoglycans; D019718:Receptors, CXCR4; D014759:Viral Envelope Proteins; D006493:Heparin